Patients with eczema are often told, gently and repeatedly, that the answer is moisturising. Use a thicker cream. Apply it more often. Avoid hot showers. These are not bad pieces of advice — barrier care matters — but they miss the underlying reality: eczema is an inflammatory disease driven by a combination of skin barrier dysfunction and a Th2-skewed immune response. Treating it as a moisturising problem alone is why so many cases plateau.
What is actually happening in eczematous skin
Atopic dermatitis involves two parallel problems. The first is structural: filaggrin and other barrier proteins are reduced or dysfunctional, allowing water loss and allergen penetration. The second is immunological: the resident immune system is biased toward a Th2 response, producing inflammatory cytokines (IL-4, IL-13, IL-31) that drive itch, redness, and chronic skin changes.
This is why moisturising alone often falls short. It addresses one layer of the problem without touching the inflammatory engine underneath.
When to think about triggers
Not all eczema is allergic, and broad allergy testing for every patient with eczema is not standard of care. However, in selected cases — particularly children with severe early-onset disease, patients whose eczema flares with clear environmental triggers, and patients with co-existing food reactions — a focused trigger work-up is appropriate. Triggers commonly worth investigating:
- Irritants: fragrances, harsh soaps, wool, lanolin, certain preservatives
- Environmental allergens: house dust mite, animal dander, pollens (in selected patients)
- Foods: mainly relevant in some paediatric cases; rarely the primary driver in adults
- Heat, sweat, and stress: not allergic but reliably exacerbate disease
First-line: barrier and topical anti-inflammatories
The foundations remain unchanged:
- Daily emollients — ceramide-containing creams or petrolatum-based products applied liberally, especially after bathing.
- Topical corticosteroids — potency matched to the body site (mid-potency for limbs, low-potency for face and folds), used in short bursts during flares.
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — non-steroid options useful for sensitive areas and maintenance.
- Topical PDE4 inhibitors (crisaborole) and topical JAK inhibitors (ruxolitinib) — newer options available depending on jurisdiction and access.
When topicals aren't enough
If a patient has body-surface involvement that cannot be controlled with topical therapy alone, or if quality of life remains significantly impaired, systemic therapy enters the conversation. Older options included cyclosporine, methotrexate, azathioprine, and phototherapy — effective but burdened with monitoring requirements and side effects.
Biologics — the new era for moderate-to-severe eczema
The arrival of targeted biologic therapy has fundamentally changed care for moderate-to-severe atopic dermatitis:
- Dupilumab (Dupixent®) blocks IL-4 receptor alpha, neutralising both IL-4 and IL-13 signalling. Approved for adults and children. Most patients achieve substantial clearance within 16 weeks.
- Tralokinumab targets IL-13 specifically.
- Oral JAK inhibitors (upadacitinib, abrocitinib) are an alternative class with rapid onset.
The biologics have transformed expectations. Patients who lived with body-wide eczema for decades on suboptimal regimens are now routinely reaching near-clear skin on a single injection every 2 to 4 weeks.
What specialist care adds
A specialist consultation can clarify whether your eczema warrants trigger investigation, confirm the diagnosis, set up a treatment ladder that matches your disease severity, and coordinate access to biologic therapy when topical regimens have failed. Most patients referred to our Allergy Rapid Access Clinic are seen within the same week.